NASDAQ$NOVT

Novanta Inc · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Novanta's financial performance remained strong despite facing significant challenges from the COVID-19 pandemic.

Novanta reported GAAP revenue of $155.5 million, a slight decrease of 1.1% compared to Q1 2019. Despite the challenges posed by the COVID-19 pandemic, the company's performance exceeded expectations for revenue, Adjusted EBITDA, and Adjusted EPS. The company ended the quarter with a strong balance sheet, including approximately $74 million in cash and cash equivalents, and a borrowing capacity of $375 million under its revolving credit facility.

  • GAAP revenue was $155.5 million, a 1.1% decrease year-over-year.
  • GAAP net income was $11.9 million, compared to $12.3 million in Q1 2019.
  • Adjusted EBITDA was $27.6 million, slightly lower than $28.2 million in the previous year.
  • Operating cash flow increased to $17.6 million from $5.5 million in Q1 2019.

Headline financials

Total Revenue

$155M

Previous: $157M-1.1%
EPS (adj)

$0.51

Previous: $0.53-3.8%
Adjusted EBITDA

$27.6M

Previous: $28.2M-2.2%
Capital Expenditures

-$2.32M

Previous: -$2.43M+4.5%
Free Cash Flow

$9.63M

Previous: $9.82M-2.0%
Net Income

$11.9M

Previous: $12.3M-2.5%
Operating Income

$13.3M

Previous: $14.4M-7.9%
Gross Profit

$64.4M

Previous: $66.3M-2.8%
Cash & Equivalents

$73.7M

Previous: $74.1M-0.5%
Total Assets

$842M

Previous: $753M+11.9%
Stock-Based Comp

$3.2M

Previous: $2.73M+17.3%

Revenue & EPS history

Novanta · Revenue · Quarterly

$155M

Q1 2020-1.1%vs Q1 2019
Beat estimate in 16 of 16 quarters(100%)
ActualEstimate

Revenue by segment

Novanta · $83.4M total across 1 segment · Q3 2023

  • Medical Solutions
    $83.4M

Forward guidance

For the second quarter of 2020, the Company expects GAAP revenue of approximately $130 million to $142 million.

Tailwinds

  • Strong bookings and shipments were seen across the board in Q1.
  • This was mostly driven by customers securing additional inventory to protect against pandemic caused supply disruptions.
  • Novanta has a strong balance sheet.
  • They have a strong innovation line-up.
  • The portfolio is well positioned with exposure to long term secular trends in robotics and automation, healthcare productivity and precision medicine.

Headwinds

  • The company expects the short-term impact of the pandemic to be significant.
  • The uncertain duration and scope of the pandemic makes it hard to estimate future impact.
  • The uncertain timing of the global public health and economic recovery makes it hard to estimate future impact.
  • Strong Q1 performance is expected to result in lower sales in Q2.
  • The company is not able at this time to reliably estimate the future impact on its operations and other financial results, including for the full year 2020.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

+2.3%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+2.7%

Avg return

30 days after

64%

41 / 64 earnings

Positive

+22.9%

Q3 2018

Best reaction

-11.3%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.2%+10.5%+11.6%
Q4 2025-2.2%-7.9%-19.4%
Q3 2025+8.4%-17.0%-10.0%
Q1 2025-1.7%+2.4%+5.3%
Q4 2024+7.2%+4.6%-4.2%
Q3 2024+4.5%+4.9%-4.5%
Q2 2024+7.6%+9.4%+10.3%
Q1 2024-1.6%+0.1%+0.8%
Q4 2023+9.9%+12.1%+11.1%
Q3 2023-11.0%-11.0%+9.4%
Q2 2023-11.3%-11.2%-6.9%
Q1 2023+2.2%+0.5%+4.8%
Q4 2022-6.1%-3.7%+1.4%
Q3 2022-3.5%+10.5%+7.2%
Q2 2022-0.4%-0.5%-13.6%
Q1 2022+3.1%+9.5%+3.9%
Q4 2021-1.0%-2.0%+4.1%
Q3 2021-7.4%-8.2%-5.7%
Q2 2021+5.1%+3.8%+8.9%
Q1 2021+2.5%+7.0%+8.1%
Q4 2020-1.3%-4.1%-0.3%
Q3 2020-2.3%-7.5%-2.3%
Q2 2020+4.8%+3.4%-6.1%
Q1 2020+6.6%+3.8%+14.2%
Q4 2019+5.6%+8.4%-10.0%
Q3 2019-5.9%-8.3%-0.1%
Q2 2019-5.3%-8.4%+2.0%
Q1 2019-5.8%-5.3%-6.9%
Q4 2018+4.7%+4.6%+8.6%
Q3 2018+22.9%+21.7%-1.9%
Q2 2018-0.6%+1.9%+13.2%
Q1 2018+2.8%+3.9%+8.1%
Q4 2017+2.8%+0.9%-4.1%
Q3 2017+10.1%+10.1%-1.5%
Q2 2017-0.8%+1.9%+4.0%
Q1 2017+8.6%+12.0%+34.0%
Q4 2016+0.2%+3.9%+5.5%
Q3 2016-1.2%+1.5%+16.9%
Q2 2016+1.7%+2.9%+7.9%
Q1 2016-0.6%
Q4 2015+2.1%
Q3 2015+2.7%
Q2 2015+1.1%
Q1 2015+0.2%
Q4 2014+1.1%
Q3 2014+0.7%
Q2 2014+4.1%
Q1 2014+1.3%
Q4 2013+2.3%
Q3 2013+9.9%
Q2 2013-4.1%
Q1 2013+0.2%
Q4 2009-1.5%
Q4 2012-1.5%
Q3 2012+0.4%
Q2 2012-8.6%
Q1 2011+10.8%
Q1 2012+2.6%
Q4 2011+0.3%
Q3 2010+6.0%
Q3 2011+6.0%
Q4 2010+18.8%
Q2 2010+18.8%
Q2 2011+18.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro